Physician profile
Anna Lowell
NPI 1700297942
$1,010.26
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $935 · 2020: $32.16 · 2021: $42.63.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $364.68 | 2019-2020 | |
| Abbvie INC. | $254.64 | 2019 | |
| Viiv Healthcare Company | $116.99 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $95.58 | 2019 | |
| Napo Pharmaceuticals INC | $73.94 | 2019 | |
| Janssen Biotech, INC. | $39.85 | 2019 | |
| Dexcom, INC. | $22.07 | 2021 | |
| Avanir Pharmaceuticals, INC. | $18.02 | 2019 | |
| Shire North American Group INC | $13.50 | 2019 | |
| Indivior INC. | $10.99 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Lowell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.